Zinger Key Points Deep Apple could receive up to $812 million in payments plus royalties from Novo Nordisk. Novo Nordisk gains exclusive global rights to commercialize oral GPCR-targeted drugs.

SOUTH SAN FRANCISCO, Calif., June 11, 2025 /PRNewswire/ -- Deep Apple Therapeutics, Inc. announced today a research collaboration and exclusive worldwide license agreement with Novo Nordisk to ...

Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...

The partnership means that Apple's fitness and wellness service will be made available to all members who enrol onto ...

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with Novo Nordisk A/S (NYSE:NVO) to discover, develop, and commercialize ...